Publication:
Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment-results from cure

dc.contributor.coauthorButtgereit, Thomas
dc.contributor.coauthorVera, Carolina
dc.contributor.coauthorAulenbacher, Felix
dc.contributor.coauthorChurch, Martin K.
dc.contributor.coauthorHawro, Tomasz
dc.contributor.coauthorAsero, Riccardo
dc.contributor.coauthorBauer, Andrea
dc.contributor.coauthorBizjak, Mojca
dc.contributor.coauthorBouillet, Laurence
dc.contributor.coauthorDissemond, Joachim
dc.contributor.coauthorFomina, Daria
dc.contributor.coauthorGimenez-Arnau, Ana M.
dc.contributor.coauthorGrattan, Clive
dc.contributor.coauthorGregoriou, Stamatios
dc.contributor.coauthorKulthanan, Kanokvalai
dc.contributor.coauthorKasPerska-Zajac, Alicja
dc.contributor.coauthorMakris, Michael
dc.contributor.coauthorKolkhir, Pavel
dc.contributor.coauthorWeller, Karsten
dc.contributor.coauthorMagerl, Markus
dc.contributor.coauthorMaurer, Marcus
dc.contributor.departmentSchool of Medicine
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:32:35Z
dc.date.issued2023
dc.description.abstractBACKGROUND: Patients with chronic spontaneous urticaria (CSU) have spontaneous wheals (W), angioedema (AE), or both, for longer than 6 weeks. Clinical differences between patients with standalone W, standalone AE, and W and AE (W+AE) remain incompletely understood. OBJECTIVE: To compare W, AE, and W+AE CSU patients regarding demographics, disease characteristics, comorbidities, disease burden, and treatment response.METHODS: Baseline data from 3,698 CSU patients in the ongoing, prospective, international, multicenter, observational Chronic Urticaria REgistry (CURE) were analyzed (data cut: September 2022).RESULTS: Across all CSU patients, 59%, 36%, and 5% had W+AE, W, and AE, respectively. The W+AE patients, compared with W and AE patients, showed the lowest male-to female ratio (0.33), higher rates of concomitant psychiatric disease (17% vs 11% vs 6%, respectively), autoimmune disease (13% vs 7% vs 9%, respectively), and nonsteroidal antiinflammatory drug (NSAID) hypersensitivity (9% vs 5% vs 2%, respectively) and the highest disease impact. The W patients, compared with W+AE and AE patients, showed the lowest rates of concomitant hypertension (15% vs 21% vs 40%, respectively) and obesity (11% vs 16% vs 17%, respectively), the highest rate of concomitant inducible urticaria (24% vs 22% vs 6%, respectively), and shorter W duration. The AE patients, compared with W+AE and W patients, were older at disease onset, showed longer AE duration, and the best response to increased doses of H1-antihistamines (58% vs 24% vs 31%, respectively) and omalizumab (92% vs 67% vs 60%, respectively).CONCLUSIONS: Our findings provide a better understanding of CSU phenotypes and may guide patient care and research efforts that aim to link them to pathogenic drivers.(c) 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue11
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipChronic Urticaria Registry (CURE) has been funded by the Urticaria Network e.V. (a German nonprofit organization) , the European Academy of Dermatology and Venereology (proposal number 2014-013) , Novartis, and Uriach. Sponsors have not been involved in the design or implementation of CURE.r Venereology (proposal number 2014-013) , Novartis, and Uriach. Sponsors have not been involved in the design or implementation of CURE. Conflicts of interest: T. Buttgereit is or recently was a speaker and/or advisor for Astra-Zeneca, BioCryst, CSL-Behring, GlaxoSmithKline (GSK) , Hexal, KalVista, Medac, Novartis, Pharming, Roche, Sanofi, and Takeda, outside the submitted work. M. K. Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach. M. Bizjak has been a speaker and advisor for Novartis, outside the submitted work. J. Dissemond received payments for consultations, lectures, and studies from Novartis. A.G.A was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceutials, Genentech, GSK, Instituto Carlos III-FEDER, Leo Pharma, Menarini, Novartis, Sanofi-Regeneron, Thermo Fisher Scientific, and Uriach Pharma/Neucor, outside the submitted work. K. Kulth-anhan received grants/research supports from Novartis; and honoraria or consultation fees from Novartis, A. Menarini, Takeda, and Sanofi. A. Kaspeska-Zajac has been a speaker for Novartis, outside the submitted work. P. Kolkhir received honoraria (advisory board, speaker) from Roche, Novartis, and Valenza Bio Inc., outside the submitted work. K. Weller received honoraria for educational lectures or for advisory activities from CSL Behring, Dr. R. Pfleger, MOXIE, Novartis, Shire/Takeda, Uriach, UCB, and Viropharma. M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regen-eron, Shire/Takeda, Third Harmonic Bio, UCB, and Uriach, all outside the submitted work.
dc.description.volume11
dc.identifier.doi10.1016/j.jaip.2023.08.020
dc.identifier.eissn2213-2201
dc.identifier.issn2213-2198
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85169512340
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2023.08.020
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26447
dc.identifier.wos1110563500001
dc.keywordsCURE registry
dc.keywordsChronic spontaneous urticaria
dc.keywordsCSU
dc.keywordsAngioedema
dc.keywordsRecurrent
dc.keywordsWithout wheals
dc.language.isoeng
dc.publisherElsevier
dc.relation.grantnoNovartis; BioCryst; CSL-Behring; KalVista; Medac; Pharming; Roche; FAES Pharma; UCB Pharma; Sanofi-Aventis; Almirall; Amgen; Takeda; Sanofi; Viropharma; Alnylam; Aralez, ArgenX; AstraZeneca; Kyowa Kirin; Leo Pharma; Lilly
dc.relation.ispartofJournal of Allergy and Clinical Immunology-in Practice
dc.subjectAllergy
dc.subjectImmunology
dc.titlePatients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment-results from cure
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorKocatürk, Emek
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files